Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1975 Feb;7(2):164–167. doi: 10.1128/aac.7.2.164

Susceptibility of Various Serogroups of Streptococci to Clindamycin and Lincomycin

Adolf W Karchmer *, Robert C Moellering Jr *, Barbara K Watson *
PMCID: PMC429097  PMID: 1137367

Abstract

The minimal inhibitory concentration of lincomycin and clindamycin for a large number of strains from multiple serogroups of streptococci was determined. The median minimal inhibitory concentration for streptococci from groups A, B, C, F, G, H, L, and M and nongroupable organisms ranged from 0.02 to 0.39 μg of lincomycin per ml and from ≤0.01 to 0.09 μg of clindamycin per ml. Among the group D strains, Streptococcus faecium and Streptococcus faecalis were resistant to lincomycin and clindamycin, whereas Streptococcus bovis and four American strains of Streptococcus durans resembled nongroup D isolates in their susceptibility to these agents. Occasional strains of nongroup D streptococci were highly resistant to lincomycin and clindamycin.

Full text

PDF
164

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. DEIBEL R. H. THE GROUP D STREPTOCOCCI. Bacteriol Rev. 1964 Sep;28:330–366. doi: 10.1128/br.28.3.330-366.1964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Dixon J. M., Lipinski A. E. Resistance of group A beta-hemolytic streptococci to lincomycin and erythromycin. Antimicrob Agents Chemother. 1972 Apr;1(4):333–339. doi: 10.1128/aac.1.4.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Facklam R. R. Comparison of several laboratory media for presumptive identification of enterococci and group D streptococci. Appl Microbiol. 1973 Aug;26(2):138–145. doi: 10.1128/am.26.2.138-145.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fass R. J., Saslaw S. Clindamycin: clinical and laboratory evaluation of parenteral therapy. Am J Med Sci. 1972 May;263(5):368–382. [PubMed] [Google Scholar]
  5. KAPLAN K., CHEW W. H., WEINSTEIN L. MICROBIOLOGICAL, PHARMACOLOGICAL AND CLINICAL STUDIES OF LINCOMYCIN. Am J Med Sci. 1965 Aug;250:137–146. doi: 10.1097/00000441-196508000-00003. [DOI] [PubMed] [Google Scholar]
  6. McCall C. E., Steigbigel N. H., Finland M. Lincomycin: activity in vitro and absorption and excretion in normal young men. Am J Med Sci. 1967 Aug;254(2):144–155. [PubMed] [Google Scholar]
  7. McGehee R. F., Jr, Smith C. B., Wilcox C., Finland M. Comparative studies of antibacterial activity in vitro and absorption and excretion of lincomycin and clinimycin. Am J Med Sci. 1968 Nov;256(5):279–292. doi: 10.1097/00000441-196811000-00002. [DOI] [PubMed] [Google Scholar]
  8. Moellering R. C., Jr, Watson B. K., Kunz L. J. Endocarditis due to group D streptococci. Comparison of disease caused by streptococcus bovis with that produced by the enterococci. Am J Med. 1974 Aug;57(2):239–250. doi: 10.1016/0002-9343(74)90448-3. [DOI] [PubMed] [Google Scholar]
  9. RANTZ L. A., RANDALL E. Use of autoclaved extracts of hemolytic streptococci for serological grouping. Stanford Med Bull. 1955 May;13(2):290–291. [PubMed] [Google Scholar]
  10. Toala P., McDonald A., Wilcox C., Finland M. Susceptibility of group D streptococcus (enterococcus) to 21 antibiotics in vitro, with special reference to species differences. Am J Med Sci. 1969 Dec;258(6):416–430. doi: 10.1097/00000441-196912000-00006. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES